benzoic acid-(16α.17β-dihydroxy-estratrien-(A)-yl-(3)-ester) | 2137-85-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: benzoic acid-(16α.17β-dihydroxy-estratrien-(A)-yl-(3)-ester)
• 英文别名: Benzoesaeure-(16α.17β-dihydroxy-oestratrien-(A)-yl-(3)-ester)；Oestriol-3-benzoat；Estriol 3-benzoate；[(8R,9S,13S,14S,16R,17R)-16,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate
• CAS: 2137-85-1
• 化学式: C₂₅H₂₈O₄
• 分子量: 392.495
• InChiKey: XOFSFAAPNZBHAY-ROHWNPGJSA-N

物化性质

• 熔点：
  227-228 °C
• 沸点：
  550.8±50.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  雌三醇 生成 benzoic acid-(16α.17β-dihydroxy-estratrien-(A)-yl-(3)-ester)
  参考文献：
  名称：

  Huffman et al., Journal of Biological Chemistry, 1940, vol. 134, p. 591,596

  摘要：

  DOI：

文献信息

• Pharmaceutical composition for treatment of osteoporosis
  申请人：NIPPON ZOKI PHARMACEUTICAL CO. LTD.

  公开号：EP0424954A1

  公开（公告）日：1991-05-02

  A pharmaceutical composition for the treatment of osteoporosis comprises an estrogen and a thyroid hormone as effective ingredients. By using the estrogen in combination with the thyroid hormone, a more excellent activity of increasing bone amount can be obtained than in the case of administering the estrogen alone.

  一种用于治疗骨质疏松症的药物组合物由雌激素和甲状腺激素作为有效成分组成。通过将雌激素与甲状腺激素结合使用，可以获得比单独使用雌激素更出色的增加骨量的活性。
• Pharmaceutical product for application to uterus mucosa
  申请人：TAKEDA CHEMICAL INDUSTRIES, Ltd.

  公开号：EP0873751A2

  公开（公告）日：1998-10-28

  A drug comprising either a peptide having the LH-RH action or an LH-RH antagonist is carried on an intrauterine contraceptive device (IUD) so as to be able to provide controlled release. Once the IUD is put in the uterus, the carried drug is gradually released over such a prolonged period of treatment time as, for example, several months to be continuously absorbed through the uterus mucosa or the vagina mucosa. This construction makes it possible to reduce the patient's pain and such a troublesomeness as frequent drug administration and continuously administer a necessary drug over a prolonged period of time while taking a contraceptive measures.

  在宫内避孕器（IUD）上携带由具有 LH-RH 作用的多肽或 LH-RH 拮抗剂组成的药物，以便能够提供控制释放。一旦将宫内避孕器放入子宫，所携带的药物就会在较长的治疗时间内（例如几个月）逐渐释放出来，通过子宫粘膜或阴道粘膜被持续吸收。这种结构可以减少病人的痛苦和频繁服药的麻烦，并在采取避孕措施的同时长期持续服用必要的药物。
• METHOD FOR IMPROVING THE AQUEOUS SOLUBILITY OF POORLY-SOLUBLE SUBSTANCES
  申请人：KABUSHIKI KAISHA SANGI

  公开号：EP2484383A1

  公开（公告）日：2012-08-08

  Provided is a method for increasing the solubility of a poorly-soluble substance used in pharmaceutical products, veterinary pharmaceutical products, quasi-drugs, cosmetic products, food products, agricultural chemicals, and the like, without using large amounts of additives. This is a method for improving aqueous solubility, which comprises coating the surface of the particle of a poorly-soluble substance used in pharmaceutical products, veterinary pharmaceutical products, quasi-drugs, cosmetic products, food products, agricultural chemicals, and the like, with microparticles of a calcium compound such as calcium phosphate or calcium carbonate.

  本发明提供了一种在不使用大量添加剂的情况下提高用于医药产品、兽医药品、准药品、化妆品、食品、农药等的难溶性物质溶解度的方法。这是一种提高水溶性的方法，它包括在用于医药产品、兽医药品、准药品、化妆品、食品、农药等的难溶性物质的颗粒表面涂上钙化合物微粒，如磷酸钙或碳酸钙。
• METHOD FOR IMPROVING WATER SOLUBILITY OF SLIGHTLY SOLUBLE SUBSTANCE
  申请人：Kabushiki Kaisha Sangi

  公开号：EP2821084A1

  公开（公告）日：2015-01-07

  It is an object of the present invention to provide a method for improving the solubility of a poorly-soluble substance, which is capable of increasing the solubility of substantially all poorly-soluble substances. This is a method comprising coating the surface of a poorly-soluble substance particle with microparticles of a calcium compound such as calcium phosphate or calcium carbonate, and at least one selected from a pH adjuster and a surfactant, by applying mechanical energy thereto.

  本发明的目的是提供一种提高难溶物质溶解度的方法，这种方法能够提高基本上所有难溶物质的溶解度。该方法包括通过机械能在难溶物质颗粒表面涂上钙化合物微粒，如磷酸钙或碳酸钙，以及至少一种选自 pH 调整剂和表面活性剂的微粒。
• SUSTAINED-RELEASE PREPARATION
  申请人：TEIJIN LIMITED

  公开号：EP0253901B1

  公开（公告）日：1991-12-27